journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Nuclear Medicine and Molecular Imaging

journal
https://www.readbyqxmd.com/read/30552447/severe-posterior-hypometabolism-but-normal-perfusion-in-a-patient-with-chronic-fatigue-syndrome-myalgic-encephalomyelitis-revealed-by-pet-mri
#1
S Sahbai, P Kauv, M Abrivard, P Blanc-Durand, M Aoun-Sebati, B Emsen, A Luciani, J Hodel, F-J Authier, E Itti
No abstract text is available yet for this article.
December 14, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30552446/treatment-of-aggressive-recurrent-meningiomas-spinning-towards-peptide-receptor-radionuclide-therapy
#2
LETTER
Eric Guedj, Thomas Graillon, Olivier Chinot, David Taieb
No abstract text is available yet for this article.
December 14, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30547207/radium-223-in-combination-with-paclitaxel-in-cancer-patients-with-bone-metastases-safety-results-from-an-open-label-multicenter-phase-ib-study
#3
Ravit Geva, Juanita Lopez, Sarah Danson, Heikki Joensuu, Avivit Peer, Samuel J Harris, Fabricio Souza, Kaline M C Pereira, Ruth Perets
PURPOSE: Concomitant treatment with radium-223 and paclitaxel is a potential option for cancer patients with bone metastases; however, myelosuppression risk during coadministration is unknown. This phase Ib study in cancer patients with bone metastases evaluated the safety of radium-223 and paclitaxel. METHODS: Eligible patients had solid tumor malignancies with ≥2 bone metastases and were candidates for paclitaxel. Treatment included seven paclitaxel cycles (90 mg/m2 per week intravenously per local standard of care; 3 weeks on/1 week off) plus six radium-223 cycles (55 kBq/kg intravenously; one injection every 4 weeks, starting at paclitaxel cycle 2)...
December 13, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30536016/predicting-pd-1-pd-l1-status-in-bladder-cancer-with-18-f-fdg-pet
#4
EDITORIAL
Emily B Ehlerding, Xiaoli Lan, Weibo Cai
No abstract text is available yet for this article.
December 11, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30535768/comprehensive-anatomical-and-functional-imaging-in-patients-with-type-i-neurofibromatosis-using-simultaneous-fdg-pet-mri
#5
Christian Philipp Reinert, Martin Ulrich Schuhmann, Benjamin Bender, Isabel Gugel, Christian la Fougère, Jürgen Schäfer, Sergios Gatidis
PURPOSE: To demonstrate the clinical use of FDG-PET/MRI for monitoring enlargement and metabolism of plexiform neurofibromas (PNF) in patients with neurofibromatosis type 1 (NF1), in whom the development of a malignant peripheral nerve sheath tumor (MPNST) is often a life limiting event. METHODS: NF1 patients who underwent a simultaneous FDG-PET/MRI examination in our institution from September 2012 to February 2018 were included. Indication was suspicion of malignant transformation of a PNF to MPNST...
December 8, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30535767/-18-f-fdg-pet-ct-diagnostic-performance-in-solitary-and-multiple-pulmonary-nodules-detected-in-patients-with-previous-cancer-history-reports-of-182-nodules
#6
Silvia Taralli, Valentina Scolozzi, Massimiliano Foti, Sara Ricciardi, Anna Rita Forcione, Giuseppe Cardillo, Maria Lucia Calcagni
PURPOSE: In oncological patients, 18 F-FDG PET/CT performance for pulmonary nodules' characterization is not well-established. Thus, the purpose of this study was to evaluate the 18 F-FDG PET/CT diagnostic performance in pulmonary nodules detected during follow-up in oncological patients and the relationship between malignancy and nodules' characteristics. METHODS: We retrospectively evaluated 182 pulmonary nodules (121 solitary, 61 multiple; mean size = 16...
December 8, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30535746/external-validation-of-a-combined-pet-and-mri-radiomics-model-for-prediction-of-recurrence-in-cervical-cancer-patients-treated-with-chemoradiotherapy
#7
François Lucia, Dimitris Visvikis, Martin Vallières, Marie-Charlotte Desseroit, Omar Miranda, Philippe Robin, Pietro Andrea Bonaffini, Joanne Alfieri, Ingrid Masson, Augustin Mervoyer, Caroline Reinhold, Olivier Pradier, Mathieu Hatt, Ulrike Schick
PURPOSE: The aim of this study was to validate previously developed radiomics models relying on just two radiomics features from 18 F-fluorodeoxyglucose positron emission tomography (PET) and magnetic resonance imaging (MRI) images for prediction of disease free survival (DFS) and locoregional control (LRC) in locally advanced cervical cancer (LACC). METHODS: Patients with LACC receiving chemoradiotherapy were enrolled in two French and one Canadian center. Pre-treatment imaging was performed for each patient...
December 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30535745/monitoring-response-of-advanced-merkel-cell-carcinoma-to-avelumab-with-18-f-fdg-pet-ct
#8
Cecilia Vellani, Daniela D'Ambrosio, Luca Licata, Ilaria Vacchieri, Antonio Bernardo, Giuseppe Trifirò
No abstract text is available yet for this article.
December 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30535744/correction-to-why-harmonization-is-needed-when-using-fdg-pet-ct-as-a-prognosticator-demonstration-with-earl-compliant-suv-as-an-independent-prognostic-factor-in-lung-cancer
#9
Benjamin Houdu, Charline Lasnon, Idlir Licaj, Guy Thomas, Pascal Do, Anne-Valerie Guizard, Cédric Desmonts, Nicolas Aide
An error occurred in the labelling of Fig. 3, where math symbols for SUV thresholds were inverted in panel b when the EARL threshold was applied to the PSF dataset and vice versa. This figure should read as follows: Fig. 3: Prognostic value of tumour SUVmax.
December 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30523391/the-diagnostic-accuracy-of-18-f-fdg-pet-ct-in-diagnosing-fracture-related-infections
#10
Justin V C Lemans, Monique G G Hobbelink, Frank F A IJpma, Joost D J Plate, Janna van den Kieboom, Paul Bosch, Luke P H Leenen, Moyo C Kruyt, Andor W J M Glaudemans, Geertje A M Govaert
PURPOSE: 18 F-Fluorodeoxyglucose positron emission tomography (18 F-FDG PET/CT) is frequently used to diagnose fracture-related infections (FRIs), but its diagnostic performance in this field is still unknown. The aims of this study were: (1) to assess the diagnostic performance of qualitative assessment of 18 F-FDG PET/CT scans in diagnosing FRI, (2) to establish the diagnostic performance of standardized uptake values (SUVs) extracted from 18 F-FDG PET/CT scans and to determine their associated optimal cut-off values, and (3) to identify variables that predict a false-positive (FP) or false-negative (FN) 18 F-FDG PET/CT result...
December 7, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30519868/ectopic-corticotropin-releasing-hormone-syndrome-caused-by-pancreatic-neuroendocrine-tumor-localized-by-68-ga-dotatate-pet-ct
#11
Guozhu Hou, Yuanyuan Jiang, Wuying Cheng
No abstract text is available yet for this article.
December 5, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30519867/joint-eanm-eano-rano-practice-guidelines-snmmi-procedure-standards-for-imaging-of-gliomas-using-pet-with-radiolabelled-amino-acids-and-18-f-fdg-version-1-0
#12
Ian Law, Nathalie L Albert, Javier Arbizu, Ronald Boellaard, Alexander Drzezga, Norbert Galldiks, Christian la Fougère, Karl-Josef Langen, Egesta Lopci, Val Lowe, Jonathan McConathy, Harald H Quick, Bernhard Sattler, David M Schuster, Jörg-Christian Tonn, Michael Weller
These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA...
December 5, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30515545/longitudinal-association-between-astrocyte-function-and-glucose-metabolism-in-autosomal-dominant-alzheimer-s-disease
#13
Stephen F Carter, Konstantinos Chiotis, Agneta Nordberg, Elena Rodriguez-Vieitez
PURPOSE: The spatial resolution of 18 F-fluorodeoxyglucose PET does not allow the specific cellular origin of its signal to be determined, but it is commonly accepted that transport and trapping of 18 F-fluorodeoxyglucose reflects neuronal glucose metabolism. The main frameworks for the diagnosis of Alzheimer's disease suggest that hypometabolism measured with 18 F-fluorodeoxyglucose PET is a biomarker of neuronal injury and neurodegeneration. There is preclinical evidence to suggest that astrocytes contribute, at least partially, to the in vivo 18 F-fluorodeoxyglucose PET signal...
December 4, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30506455/prediction-of-therapy-response-in-bone-predominant-metastatic-breast-cancer-comparison-of-18-f-fluorodeoxyglucose-and-18-f-fluoride-pet-ct-with-whole-body-mri-with-diffusion-weighted-imaging
#14
Gurdip K Azad, Benjamin P Taylor, Adrian Green, Ines Sandri, Angela Swampillai, Mark Harries, Hartmut Kristeleit, Janine Mansi, Vicky Goh, Gary J R Cook
PURPOSE: To compare [18 F]-fluorodeoxyglucose (FDG) and [18 F]-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance with diffusion-weighted imaging (WB-MRI), for endocrine therapy response prediction at 8 weeks in bone-predominant metastatic breast cancer. PATIENTS AND METHODS: Thirty-one patients scheduled for endocrine therapy had up to five bone metastases measured [FDG, NaF PET/CT: maximum standardized uptake value (SUVmax ); WB-MRI: median apparent diffusion coefficient (ADCmed )] at baseline and 8 weeks...
December 1, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30506283/personalized-177-lu-octreotate-peptide-receptor-radionuclide-therapy-of-neuroendocrine-tumours-initial-results-from-the-p-prrt-trial
#15
Michela Del Prete, François-Alexandre Buteau, Frédéric Arsenault, Nassim Saighi, Louis-Olivier Bouchard, Alexis Beaulieu, Jean-Mathieu Beauregard
PURPOSE: Peptide receptor radionuclide therapy (PRRT) is mostly administered using a fixed injected activity (IA) per cycle. This empiric regime results in highly variable absorbed doses to the critical organs and undertreatment of the majority of patients. We conceived a personalized PRRT protocol in which the IA is adjusted to deliver a prescribed absorbed dose to the kidney, with the aim to safely increase tumour irradiation. We herein report on the initial results of our prospective study of personalized PRRT, the P-PRRT Trial (NCT02754297)...
November 30, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30498897/safety-and-efficacy-of-targeted-alpha-therapy-with-213-bi-dota-substance-p-in-recurrent-glioblastoma
#16
Leszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska, Henryk Koziara, Bartosz Królicki, Maciej Jakuciński, Dariusz Pawlak, Christos Apostolidis, Saed Mirzadeh, Rafał Rola, Adrian Merlo, Alfred Morgenstern
Treatment options for recurrent glioblastoma multiforme (GBM) are very limited. GBM cells express high levels of the GPCR neurokinin type 1 receptor (NK-1R), and a modified substance P can be used as its ligand for the tumor cell targeting. Targeted alpha therapy with DOTA-Substance P labeled with the short range alpha emitter 213 Bi allows for selective irradiation and killing of tumor cells. MATERIAL AND METHODS: Twenty patients with recurrent GBM were included into the study following a standard therapy...
November 29, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30488099/clinical-impact-of-68-ga-psma-11-pet-on-patient-management-and-outcome-including-all-patients-referred-for-an-increase-in-psa-level-during-the-first-year-after-its-clinical-introduction
#17
Julian Müller, Daniela A Ferraro, Urs J Muehlematter, Helena I Garcia Schüler, Sarah Kedzia, Daniel Eberli, Matthias Guckenberger, Stephanie G C Kroeze, Tullio Sulser, Daniel M Schmid, Aurelius Omlin, Alexander Müller, Thomas Zilli, Hubert John, Helmut Kranzbuehler, Philipp A Kaufmann, Gustav K von Schulthess, Irene A Burger
PURPOSE: The fast-increasing use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) ligand for the imaging of prostate cancer (PCA) biochemical recurrence has led to a rapid change in treatment concepts. Since the superiority of 68 Ga-PSMA-11 PET in detecting recurrent PCA is well established, the aim of our study was to assess its effect on management and outcome in all patients imaged during the first year after its introduction into clinical routine...
November 28, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30488098/prognostic-value-of-baseline-metabolic-tumor-volume-measured-on-18-f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-in-melanoma-patients-treated-with-ipilimumab-therapy
#18
Kimiteru Ito, Heiko Schöder, Rebecca Teng, John L Humm, Ai Ni, Jedd D Wolchok, Wolfgang A Weber
PURPOSE: Ipilimumab induces durable remission in about 15-20% of patients with metastatic melanoma. However, reliable predictors of response to ipilimumab are currently lacking. Whole-body metabolic tumor volume (wMTV) has been shown to be a strong prognostic factor in a variety of malignancies treated with chemotherapy, but few results have been reported for patients treated with immunotherapy. The purpose of this study was to investigate the prognostic value of wMTV and other metabolic parameters from baseline 18 F-FDG PET/CT scans in patients with melanoma being treated with ipilimumab...
November 28, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30474706/outcome-and-safety-of-rechallenge-177-lu-lu-psma-617-in-patients-with-metastatic-prostate-cancer
#19
Anna Yordanova, Paula Linden, Stefan Hauser, Michael Meisenheimer, Stefan Kürpig, Georg Feldmann, Florian C Gaertner, Markus Essler, Hojjat Ahmadzadehfar
BACKGROUND: Data are sparse regarding the feasibility of radioligand therapy (RLT) with [177 Lu]Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of rechallenge PSMA-RLT in patients with progressive prostatic cancer who previously benefited from this therapy. MATERIALS AND METHODS: Patients who received rechallenge therapy at our department from January 2015 to March 2018 were assessed. Non-haematological and haematological adverse events were evaluated from laboratory data and clinical reports and were graded according to the Common Terminology Criteria for Adverse Events (CTCAE v...
November 24, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/30467786/first-steps-in-an-uncharted-territory-by-wfnmb
#20
Dong Soo Lee, Patricia Bernal Trujillo, Savvas Frangos
No abstract text is available yet for this article.
November 22, 2018: European Journal of Nuclear Medicine and Molecular Imaging
journal
journal
20104
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"